Compare Abbott Laboratories (ABT) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Annaly Capital Management, Inc. — how do they compare? Abbott Laboratories trades at $95.42 (market cap $166.94B), while Annaly Capital Management, Inc. trades at $22.61 (market cap $16.63B). The key difference: Abbott Laboratories is far larger — about 10× Annaly Capital Management, Inc.'s market cap, and Annaly Capital Management, Inc. pays the higher dividend (13.22%). Which is the better fit depends on your goals.
| ABT | NLY | |
|---|---|---|
Market Cap | $166.94B | $16.63B |
Sector | Health | Financials |
52-Week High | $136.62 | $24.40 |
52-Week Low | $82.57 | $19.47 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 13.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Annaly Capital Management (NLY) trades at $22.69, up 0.58% with a bullish technical outlook. The stock shows strong fundamentals with a P/E of 7.42, ROE of 15.61%, and consistent earnings beats in recent quarters. Recent dividend increases to $0.75 per share and positive analyst coverage highlight income appeal. The company maintains solid liquidity despite significant investing outflows.
NLY presents a compelling income opportunity with a 13.2% dividend yield and analyst consensus target of $24.40. However, risks include interest rate sensitivity, high leverage (debt-to-asset ratio of 23.55), and volatile cash flow patterns. The stock offers 7.5% upside potential but requires monitoring of Federal Reserve policy impacts on mortgage REITs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
